Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Crisaborole
Drug ID BADD_D02450
Description Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis. This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older. It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile. Its structure contains a boron atom, which facilitates skin penetration and binding to the bimetal center of the phosphodiesterase 4 enzyme. It is currently under development as topical treatment of psoriasis.
Indications and Usage Intended for the topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.
Marketing Status approved; investigational
ATC Code D11AH06
DrugBank ID DB05219
KEGG ID D10873
MeSH ID C543085
PubChem ID 44591583
TTD Drug ID D08NWF
NDC Product Code 0009-0211; 11722-066; 57572-0715; 60715-3211; 69037-0041; 51686-0005; 57572-0714; 17337-0546; 46438-0656; 58175-0622; 69575-4035; 69766-043; 55724-211
UNII Q2R47HGR7P
Synonyms crisaborole | Eucrisa | AN2728 | AN-2728 | 5-(4-cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole
Chemical Information
Molecular Formula C14H10BNO3
CAS Registry Number 906673-24-3
SMILES B1(C2=C(CO1)C=C(C=C2)OC3=CC=C(C=C3)C#N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acne23.02.01.0010.002802%Not Available
Application site erythema12.07.01.001; 08.02.01.001; 23.03.06.0050.031955%Not Available
Application site irritation12.07.01.003; 08.02.01.0030.005001%Not Available
Application site pain12.07.01.004; 08.02.01.0040.197864%Not Available
Application site pruritus08.02.01.005; 23.03.12.004; 12.07.01.0050.012449%Not Available
Application site rash23.03.13.008; 12.07.01.016; 08.02.01.0160.004008%Not Available
Application site reaction12.07.01.006; 08.02.01.0060.002110%Not Available
Application site warmth12.07.01.029; 08.02.01.0290.001809%Not Available
Blepharitis23.03.04.012; 06.04.04.0010.001206%Not Available
Blister23.03.01.001; 12.01.06.0020.005604%Not Available
Burning sensation08.01.09.029; 17.02.06.0010.138778%Not Available
Cheilitis23.03.03.025; 07.05.01.0010.000904%
Condition aggravated08.01.03.0040.045290%Not Available
Crying17.02.05.013; 12.02.11.001; 08.01.03.005; 19.04.02.0020.004611%Not Available
Dermatitis23.03.04.0020.003618%Not Available
Dermatitis allergic23.03.04.003; 10.01.03.0140.000904%Not Available
Dermatitis atopic23.03.04.016; 10.01.04.0040.016846%Not Available
Dermatitis contact12.03.01.040; 10.01.01.003; 23.03.04.0040.004912%Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.0040.000177%
Discomfort08.01.08.0030.002199%Not Available
Drug hypersensitivity10.01.01.0010.025252%Not Available
Drug ineffective08.06.01.0060.108668%Not Available
Dry skin23.03.03.0010.007324%
Eczema23.03.04.0060.015942%
Erythema23.03.06.0010.027663%Not Available
Erythema of eyelid23.03.06.006; 06.04.04.0030.000904%Not Available
Eye inflammation06.04.05.0020.000603%Not Available
Eye irritation06.04.05.0030.005604%Not Available
Eye pain06.08.03.0020.002500%
Eye swelling06.08.03.0030.003884%Not Available
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages